FDA Wants Drug Pulled From Market, Citing Liver Risk. Company Says No

(MedPage Today) — The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to pull the drug from the market…

Source link : https://www.medpagetoday.com/rheumatology/generalrheumatology/119741

Author :

Publish date : 2026-02-04 21:29:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

FDA Wants Drug Pulled From Market, Citing Liver Risk. Company Says No

Particle Pollution From Wildfire Smoke Tied to 24,000 U.S. Deaths Each Year

‘Most Compelling’ Data Yet for Metastasis-Directed Therapy in Prostate Cancer

Related Posts

Period blood test could be alternative to cervical screening, study says

Autism Prevalence in Girls and Boys May Be Nearly Equal, Study Suggests

‘Time Is Brain’ Again, Now for Hemostatic Control of Intracerebral Bleeds

Dems Hijack CMS Fraud Hearing, Cast Spotlight on ‘Federal Terror’ Campaign

Heart Attack, Stroke Risk Rises After Serious RSV, Study Says

More Evidence That Removing Fallopian Tubes Dramatically Reduces Ovarian Cancer Risk

Period blood test could be alternative to cervical screening, study says

Autism Prevalence in Girls and Boys May Be Nearly Equal, Study Suggests

‘Time Is Brain’ Again, Now for Hemostatic Control of Intracerebral Bleeds

Dems Hijack CMS Fraud Hearing, Cast Spotlight on ‘Federal Terror’ Campaign

Heart Attack, Stroke Risk Rises After Serious RSV, Study Says

More Evidence That Removing Fallopian Tubes Dramatically Reduces Ovarian Cancer Risk

‘Most Compelling’ Data Yet for Metastasis-Directed Therapy in Prostate Cancer

FDA Wants Drug Pulled From Market, Citing Liver Risk. Company Says No

Categories

Archives